Lumos Diagnostics institutional component completion announcement

Lumos Diagnostics Holdings Limited (ASX:LDX) has successfully completed the institutional component of its A$10.0 million equity raising, raising approximately A$3.1 million from institutional and sophisticated investors. The institutional component, which opened on Wednesday, 4 September 2024 and closed on Thursday, 5 September 2024, saw strong support from eligible institutional shareholders. The retail component of the Entitlement Offer is expected to raise approximately A$6.9 million and is set to open on Wednesday, 11 September 2024, closing at 5.00pm (AEST) on Wednesday, 2 October 2024. Shares in Lumos are expected to recommence trading on an ex-entitlement basis from market open today.

Executive Commentary on Completion of Institutional Entitlement Offer

The successful completion of the institutional component of the entitlement offer marks a significant milestone for Lumos Diagnostics. The strong support from eligible institutional shareholders reflects their confidence in our company's growth prospects and strategic initiatives. The funds raised will be instrumental in advancing our ongoing projects, including the completion of the FebriDx CLIA waiver trial in the US, product development, sales and marketing activities, and working capital requirements. We are committed to utilizing these funds effectively to drive our business forward and deliver long-term value to our shareholders.

Summary of Lumos Diagnostics Entitlement Offer Completion

Lumos Diagnostics Holdings Limited has successfully completed the institutional component of its A$10.0 million equity raising, raising approximately A$3.1 million from institutional and sophisticated investors. The retail component of the Entitlement Offer is expected to raise approximately A$6.9 million and is set to open on Wednesday, 11 September 2024, closing at 5.00pm (AEST) on Wednesday, 2 October 2024. The company intends to utilize the proceeds to fund the completion of the FebriDx CLIA waiver trial in the US, product development, sales and marketing activities, and working capital purposes. The successful completion of the institutional component reflects strong support from eligible institutional shareholders, underlining confidence in Lumos Diagnostics' strategic direction and growth trajectory.